Digicann Ventures Valuation

Is VY3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VY3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VY3's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VY3's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VY3?

Other financial metrics that can be useful for relative valuation.

VY3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.8x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does VY3's PE Ratio compare to its peers?

The above table shows the PE ratio for VY3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average1.5x
ECX Epigenomics
0.2xn/a€705.4k
CNNC Cannonau
3xn/aUS$1.0m
SE Sweet Earth Holdings
2xn/aCA$372.0k
KAYS Kaya Holdings
0.6xn/aUS$929.9k
VY3 Digicann Ventures
0.03xn/a€441.1k

Price-To-Earnings vs Peers: VY3 is good value based on its Price-To-Earnings Ratio (0x) compared to the peer average (1.5x).


Price to Earnings Ratio vs Industry

How does VY3's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a17.9%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: VY3 is good value based on its Price-To-Earnings Ratio (0x) compared to the European Pharmaceuticals industry average (21.5x).


Price to Earnings Ratio vs Fair Ratio

What is VY3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VY3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.03x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VY3's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies